Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ari Zimran

Showing results (221-230 of 238) with videos related to

Pageof 24
Sort By:
Journal of Clinical Medicine|June 27, 2024
Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient RegistryDeborah Elstein, Nadia Belmatoug, Bruno Bembi, et al.
Orphanet Journal of Rare Diseases|September 28, 2013
Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher diseaseYildiz Yildiz, Per Hoffmann, Stefan Vom Dahl, et al.
Clinical and Translational Medicine|May 20, 2022
Identification of a novel therapeutic target underlying atypical manifestation of Gaucher diseaseEun Na Kim, Hyo-Sang Do, Hwangkyo Jeong, et al.
American Journal of Hematology|February 19, 2021
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life dataMajdolen Istaiti, Shoshana Revel-Vilk, Michal Becker-Cohen, et al.
American Journal of Hematology|February 13, 2013
Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher diseaseHadhami Ben Turkia, Derlis E Gonzalez, Norman W Barton, et al.
Blood Cells, Molecules & Diseases|December 22, 2009
Guidelines for the restart of imiglucerase in patients with Gaucher disease: recommendations from the European Working Group on Gaucher diseaseCarla E M Hollak, Johannes M F G Aerts, Nadia Belmatoug, et al.
Molecular Genetics and Metabolism|August 30, 2017
Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physiciansAtul Mehta, Nadia Belmatoug, Bruno Bembi, et al.
Journal of Inherited Metabolic Disease|February 10, 2018
Hepatocellular carcinoma in Gaucher disease: an international case seriesMartine Regenboog, Laura van Dussen, Joanne Verheij, et al.
American Journal of Hematology|January 23, 2013
Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imigluceraseAri Zimran, Gregory M Pastores, Anna Tylki-Szymanska, et al.
Neurology. Genetics|May 21, 2021
Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher DiseaseLais M Oliveira, Tara Rastin, Graeme A M Nimmo, et al.
Pageof 24

Showing results (221-230 of 238) with videos related to

Sort By:
Pageof 24
Journal of Clinical Medicine|June 27, 2024
Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient RegistryDeborah Elstein, Nadia Belmatoug, Bruno Bembi, et al.
Orphanet Journal of Rare Diseases|September 28, 2013
Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher diseaseYildiz Yildiz, Per Hoffmann, Stefan Vom Dahl, et al.
Clinical and Translational Medicine|May 20, 2022
Identification of a novel therapeutic target underlying atypical manifestation of Gaucher diseaseEun Na Kim, Hyo-Sang Do, Hwangkyo Jeong, et al.
American Journal of Hematology|February 19, 2021
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life dataMajdolen Istaiti, Shoshana Revel-Vilk, Michal Becker-Cohen, et al.
American Journal of Hematology|February 13, 2013
Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher diseaseHadhami Ben Turkia, Derlis E Gonzalez, Norman W Barton, et al.
Blood Cells, Molecules & Diseases|December 22, 2009
Guidelines for the restart of imiglucerase in patients with Gaucher disease: recommendations from the European Working Group on Gaucher diseaseCarla E M Hollak, Johannes M F G Aerts, Nadia Belmatoug, et al.
Molecular Genetics and Metabolism|August 30, 2017
Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physiciansAtul Mehta, Nadia Belmatoug, Bruno Bembi, et al.
Journal of Inherited Metabolic Disease|February 10, 2018
Hepatocellular carcinoma in Gaucher disease: an international case seriesMartine Regenboog, Laura van Dussen, Joanne Verheij, et al.
American Journal of Hematology|January 23, 2013
Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imigluceraseAri Zimran, Gregory M Pastores, Anna Tylki-Szymanska, et al.
Neurology. Genetics|May 21, 2021
Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher DiseaseLais M Oliveira, Tara Rastin, Graeme A M Nimmo, et al.
Pageof 24